Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: firstname.lastname@example.org
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.
Sacituzumab Govitecan/Pembrolizumab Shows Early Antitumor Activity in Metastatic NSCLC
The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.
Lutetium Lu 177 Vipivotide Tetraxetan Generates Enhanced Antitumor Activity in Patients With mCRPC
Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.
Adagrasib Elicits Intracranial Response in NSCLC With KRAS G12C Mutations, Untreated CNS Metastases
Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.
Fixed-Duration Ibrutinib/Venetoclax Improves PFS in Patients With CLL and High-Risk Genomic Features
The complete response or complete response with incomplete bone marrow recovery rate was 61% for patients with chronic lymphocytic leukemia and high-risk disease.
FDA Approves Talazoparib In Combination With Enzalutamide for mCRPC
The PARP inhibitor talazoparib has been approved in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.
Lower Trastuzumab Deruxtecan Dose Appears Optimal in HER2+ mCRC
Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.
Increasing Nurse Autonomy in Managing Infusion-Related Reactions Is Paramount
Appropriate monitoring of infusion-related reactions requires up-to-date knowledge of the latest criteria for adverse event management, health system policies, and protocols for reporting.
Erdafitinib Reduces Risk of Death by 36% in FGFR-Altered Urothelial Cancer
Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.
FDA Approves Radiohybrid PET Diagnostic Agent Posluma for PSMA-Positive Lesions in Prostate Cancer
The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer
Heath-related QOL Maintained Longer With Trastuzumab Deruxtecan in HER2+ mBC
The time to definitive deterioration was delayed among patients receiving trastuzumab deruxtecan vs treatment of physician’s choice in all prespecified scales in DESTINY-Breast02.
Recognizing Maladaptive Coping and Building Resilience in Oncology Nursing Is Vital
Acknowledging and addressing maladaptive coping mechanisms may help reduce moral distress and burnout among oncology nurses.
Avasopasem Manganese Significantly Reduces IMRT-Induced Severe Oral Mucositis, Is Feasible in Clinical Workflow
Elizabeth R. Cullen, MSN, ARNP, highlights the efficacy of avasopasem manganese in mitigating severe oral mucositis in patients with locally advanced head and neck cancer.
Oncology Nurses Play a Vital Role in Fostering Biomarker Testing Conversations With Patients
Julie C. Martin DNP, AOCN, FNP-BC, discusses best practices to approaching conversations on clinically actionable genomic results with patients.
Radiation Therapy Adverse Effect Management Requires Long-term Monitoring
Ashley Marenyi, RN, BSN, OCN, highlights the importance of counseling patients with head and neck cancer on the short-term and long-term adverse effects of radiation treatment.
Onco-Nursing Experts Define Best Practices, Treatment Considerations for Managing Patients With MPNs
Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Trastuzumab Deruxtecan Shows Promise as a Treatment for Patients With HER2+ Uterine Carcinosarcoma
The antibody-drug conjugate trastuzumab deruxtecan has demonstrated clinical activity among patients with uterine carcinosarcomas, regardless of HER2 expression level.
Pembrolizumab Receives Full FDA Approval for Treatment of Select Patients With dMMR/MSI-H Solid Tumors
The FDA has granted full approval to pembrolizumab (Keytruda) for certain adult and pediatric patients with advanced MSI-H or dMMR solid tumors.
FDA Approves Dabrafenib With Trametinib for Pediatric BRAF V600E–mutant Low-grade Glioma
FDA has approved the BRAF/MEK combination of dabrafenib plus trametinib for pediatric BRAF V600E–mutant low-grade glioma. The label comes with a warning for pyrexia.
Frontline Abiraterone/Olaparib Prolongs Survival vs SOC in mCRPC
The median overall survival was 42.1 months with abiraterone plus olaparib and 34.7 months with abiraterone plus placebo in patients with metastatic castration-resistant prostate cancer.
Ponatinib Plus Reduced-Intensity Chemotherapy Outperforms Imatinib in Newly Diagnosed Ph+ ALL
Frontline ponatinib plus reduced-intensity chemotherapy yielded a higher minimal residual disease-negative complete remission rate than imatinib in the phase 3 PhALLCON study.
FDA Grants Regular Approval to Dostarlimab for dMMR Endometrial Cancer
Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.
FDA Approves Oral SERD Elacestrant for ESR1-Mutant ER+, HER2– Metastatic Breast Cancer
The FDA has granted an accelerated approval to elacestrant (Orserdu) for the treatment of patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer following at least 1 prior lines of endocrine therapy.
Adjuvant Pembrolizumab Gets FDA Approval in NSCLC
Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IB, II, or IIIA following resection and platinum-based chemotherapy.
Tucatinib and Trastuzumab Combination Gains FDA Approval for RAS Wild-Type HER2+ mCRC
The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.
Real-World Patient-Reported Outcomes for Axi-Cel Align With Clinical Trial QOL, Symptomology Data
Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.
Adjuvant Abemaciclib Plus Endocrine Therapy Sustains Benefit for Patients With HR+/HER2– High-Risk Early Breast Cancer
A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Significant Gaps Still Remain in The Treatment of Breast Cancer
During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.
Trastuzumab Deruxtecan Continues to Elicit Encouraging Responses in Patients With Metastatic Gastric/GEJ Cancer
After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.
FDA Schedules ODAC Meetings to Review Pending Drug Applications
The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512